When does Hemlibra’s (emicizumab) patent expire?
Hemlibra’s patent expiry depends on the specific patent family and country. Patent terms typically run from the filing date of the relevant patent, and different patents can expire at different times, even within the same drug. Because the exact expiry date varies by jurisdiction and by which patent you mean (the original patent vs later patents covering formulations, dosing, or manufacturing), you need the patent number or the country to give a single definitive “expiry date.”
Which country’s patent expiry are you looking for?
Hemlibra’s availability and exclusivity timing differ by market:
- United States vs European Union vs UK vs other countries can have different patent filing dates and term adjustments.
- “Patent expiry” is not always the same as market exclusivity or biologic exclusivity periods that may keep biosimilars from launching even after some patents end.
How can you find the exact Hemlibra patent expiry date?
To pinpoint the exact expiration date, look up:
1) the patent(s) for Hemlibra in the target country, and
2) the specific patent family covering the method/compound/composition claims you care about.
If you tell me the country (e.g., US, UK, EU/EP, Canada) and whether you mean the main compound patent or any specific patent number, I can narrow it to the correct expiry timeline.
Is there a single “Biosimilar entry date” instead of patent expiry?
Companies and patients often look for a practical launch date for biosimilars, which may be driven by:
- the last expiring relevant patent(s),
- any regulatory exclusivity that blocks approval or marketing,
- and litigation outcomes if other companies are challenging those patents.
If you share the region you care about, I can align “patent expiry” with the likely biosimilar launch constraints in that market.
Sources
No sources were provided in the prompt, so I can’t cite Hemlibra-specific patent expiry dates accurately.